These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 33904468)

  • 1. Predicting Long-Term Outcome of Patients of Early Parkinsonism with Acute Levodopa Challenge Test.
    Acharya M; Banerjee S; Chatterjee A; Mukherjee A; Biswas S; Gangopadhyay G; Biswas A
    Neurol India; 2021; 69(2):430-434. PubMed ID: 33904468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute challenge with apomorphine and levodopa in Parkinsonism.
    Rossi P; Colosimo C; Moro E; Tonali P; Albanese A
    Eur Neurol; 2000; 43(2):95-101. PubMed ID: 10686467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dyskinesia in multiple system atrophy and progressive supranuclear palsy.
    Jost WH; Lingor P; Tönges L; Schwarz J; Buhmann C; Kassubek J; Schrag A
    J Neural Transm (Vienna); 2019 Jul; 126(7):925-932. PubMed ID: 31087195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does clinical intolerance to a diagnostic acute levodopa challenge differentiate multiple system atrophy from PD?
    Estévez S; Perez-Lloret S; Merello M
    Int J Neurosci; 2009; 119(12):2257-61. PubMed ID: 19916854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Affective symptoms in multiple system atrophy and Parkinson's disease: response to levodopa therapy.
    Fetoni V; Soliveri P; Monza D; Testa D; Girotti F
    J Neurol Neurosurg Psychiatry; 1999 Apr; 66(4):541-4. PubMed ID: 10201434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment.
    Thanvi B; Lo N; Robinson T
    Postgrad Med J; 2007 Jun; 83(980):384-8. PubMed ID: 17551069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
    Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
    Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choreiform dyskinesias following levodopa treatment of parkinsonism due to osmotic demyelination syndrome.
    de Souza A; de Souza RJ
    Parkinsonism Relat Disord; 2017 Oct; 43():120-121. PubMed ID: 28729089
    [No Abstract]   [Full Text] [Related]  

  • 9. Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation.
    Li MH; Mestre TA; Fox SH; Taati B
    J Neuroeng Rehabil; 2018 Nov; 15(1):97. PubMed ID: 30400914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resting-state connectivity predicts levodopa-induced dyskinesias in Parkinson's disease.
    Herz DM; Haagensen BN; Nielsen SH; Madsen KH; Løkkegaard A; Siebner HR
    Mov Disord; 2016 Apr; 31(4):521-9. PubMed ID: 26954295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa-induced dyskinesia: clinical features, incidence, and risk factors.
    Tran TN; Vo TNN; Frei K; Truong DD
    J Neural Transm (Vienna); 2018 Aug; 125(8):1109-1117. PubMed ID: 29971495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia.
    Steece-Collier K; Stancati JA; Collier NJ; Sandoval IM; Mercado NM; Sortwell CE; Collier TJ; Manfredsson FP
    Mov Disord; 2019 May; 34(5):697-707. PubMed ID: 31002755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa-Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
    Güttler C; Altschüler J; Tanev K; Böckmann S; Haumesser JK; Nikulin VV; Kühn AA; van Riesen C
    Mov Disord; 2021 Apr; 36(4):927-937. PubMed ID: 33247603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Side effects induced by the acute levodopa challenge in Parkinson's Disease and atypical parkinsonisms.
    Vasta R; Nicoletti A; Mostile G; Dibilio V; Sciacca G; Contrafatto D; Cicero CE; Raciti L; Luca A; Zappia M
    PLoS One; 2017; 12(2):e0172145. PubMed ID: 28207803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
    Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF
    Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bilateral low frequency rTMS of the primary motor cortex may not be a suitable treatment for levodopa-induced dyskinesias in late stage Parkinson's disease.
    Flamez A; Cordenier A; De Raedt S; Michiels V; Smetcoren S; Van Merhaegen-Wieleman A; Parys E; De Keyser J; Baeken C
    Parkinsonism Relat Disord; 2016 Jan; 22():54-61. PubMed ID: 26777410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia.
    Ueno T; Yamada J; Nishijima H; Arai A; Migita K; Baba M; Ueno S; Tomiyama M
    Neurobiol Dis; 2014 Apr; 64():142-9. PubMed ID: 24398173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal bidirectional plasticity-like effects in Parkinson's disease.
    Huang YZ; Rothwell JC; Lu CS; Chuang WL; Chen RS
    Brain; 2011 Aug; 134(Pt 8):2312-20. PubMed ID: 21742734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noradrenergic drugs for levodopa-induced dyskinesia.
    Colosimo C; Craus A
    Clin Neuropharmacol; 2003; 26(6):299-305. PubMed ID: 14646609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.